AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

About EpiClick ™ Technology EpiClick ™ Technology is a platform for creating customizable, multispecific antibodies that target previously undruggable epitopes, including those on PD-1 ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

The study enrolled patients with a PD-L1 combined positive score (CPS) of 10 or more, matching Keytruda's label in first-line ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...

This is only the beginning, as its second radiotherapeutic is known as Lu-RAD202, which is being developed to target HER2 ... 1 study, using 177-LuRAD204 to treat these metastatic NSCLC patients ...